Dr Peter McCullough: Prescription and Over-the-Counter Treatments for Long COVID Syndrome (2023)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Over three years into the pandemic with nearly the entire country having become
sick with SARS-CoV-2, a virus engineered to invade the body, there are millions
suffering with long-hauler syndrome. Approximately half of patients admitted to
the ICU with COVID-19 will have post-COVID syndrome which is now understood to
be due to persistence of the SARS-CoV-2 Spike protein within cells, tissues, and
organs. Those vaccinated have been additionally loaded with Spike, so may have
even a worse course with prolonged symptoms including fatigue, lethargy, brain
fog, muscle loss, skin and hair changes, sleeplessness, and effort intolerance.
The magnitude of the problem has driven an all-encompassing search for
management strategies to resolve the syndrome(s).
Hope is on the
horizon with a preprint paper published by Halma et al summarizing the
prescription drug and over-the-counter candidates for therapy. In my practice, I
stylize the approach based on the patient and how recent the COVID-19 infection
was in their history. If there are lingering signs of infection, then a course
of full dose ivermectin can be considered. Aspirin is reasonable given increased
rates of heart attack and stroke after the illness. I have found the colchicine
appears to have an important role in pleurodynia or chest wall discomfort.
Additionally it is used with corticosteroids in vaccine-induced myopericarditis.
Low-dose naltrexone has been reported to ameliorate fatigue and inanition.
Metformin has supportive data and would be appropriate in pre-diabetes and those
with diabetes mellitus.
Halma, M.T.; Plothe, C.; Lawrie, T. Strategies for the
Management of Spike Protein-Related Pathology. Preprints 2023,
2023030344. https://doi.org/10.20944/preprints202303.0344.v1.
From the OTC list, I have found nattokinase, the Japanese product derived
from natto (a traditionalJapanese food made from whole soybeans that have been fermented with Bacillus subtilis var. natto.) to be the most compelling and scientifically supported approach to
clear Spike protein out of the body via proteolytic degradation. A host of
cellular protective, anti-oxidant approaches are listed with vitamin C and
NAC being readily available and widely used.
Nattokinase and Spike Protein
Tanikawa et al. examined the effect of nattokinase on the spike protein of SARS-CoV-2. In
the first experiment, they demonstrated that spike was degraded in a time
and dose-dependent manner in a cell lysate preparation that could be
analogous to a vaccine recipient. The second experiment demonstrated that
nattokinase degraded the spike protein in SARS-CoV-2 infected cells. This
was reproduced in a similar study done by Oba and colleagues in 2021.
Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R,
Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of
SARS-CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi:
10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary
according to purity. Kurosawa and colleagues have shown in humans that after
a single oral dose of 2000 FU D-dimer concentrations at six, and
eight hours, and blood fibrin/fibrinogen degradation products at four hours
after administration elevated significantly (p < 0.05, respectively).
Thus
an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic
and pharmacodynamic studies have not been completed, but several years of
market use as an over-the-counter supplement suggests nattokinase is safe
with the main caveat being excessive bleeding and cautions with concurrent
antiplatelet and anticoagulant drugs.
Ivermectin and Spike Protein
Former NIH researcher David Scheim, PhD, early in the pandemic proposed that
SARS-CoV-2 Spike protein was acting like a grappling hook pulling together
circulating red blood cells (RBSc) into long chains and clumps in a process
called hemagglutination (HA). This explained why the red blood cells could
not carry oxygen normally and was congruent with the finding of micro blood
clots in the lungs. Recently, Boschi et al have provided additional support
for this mechanism (source).
According to the authors: “Ivermectin blocked HA when
added to RBCs prior to spike protein and reversed HA when added
afterwards.”
In another spectacular publication, Stone et al,
describes the prompt improvement of oxygenation in patients with ivermectin
(source).
The published oxygenation curves from multiple studies clearly
show this physiological effect of ivermectin occurs so rapidly, it must be
explained by a direct anti-Spike protein effect of ivermectin. An
anonymous video of a critically ill man
demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have
described in the Figure above. So for the next critically ill patient with
COVID-19, if the opportunity presents itself, push for the administration of
ivermectin. This is the only published therapy for COVID-19 that improves
oxygen saturation while the patient mounts a recovery. As in this man, it
may be the critical factor for a turnaround and a chance to walk out of the
hospital.
Key Takeaway
Patients should push their doctors to refer them to clinical trials, and
when that is not feasible, then empiric therapy can be pursued. It is
important to realize that in the absence of completed large randomized
placebo controlled randomized trials, which are easily 5 or more years away
in the future, no therapeutic claims can be made. In the meantime we must be
perceptive as patients and open-minded as clinicians to come up with
reasonable approaches that can be used to help those sick now with
post-COVID syndromes.
Though there are many long haulers treatment protocols out there, we
consider and recommend the I-Recover protocol as one of the best.
Given the lack of clinical trials of long-haul COVID-19 syndrome,
these recommendations are based on the abnormal changes within the
body associated with the COVID-19 disease and post viral illnesses
along with the collective experience of FLCCC members.
This protocol has also been used to treat post-vaccine inflammatory
syndromes with similar success. As with all FLCCC Alliance protocols,
the components, doses, and durations will evolve as more clinical data
accumulates.
Due to the marked overlap between long COVID and post-vaccine syndrome,
please refer to the I-RECOVER Post-Vaccine Treatment protocol for detailed treatment strategies.
The Wellness Company's acclaimed Spike Support Formula contains scientifically-researched
ingredients, including nattokinase, black seed oil, green tea extract
and selenium.
These ingredients are known for their ability
to dissolve spike protein, prevent it from binding to cells, and
repair tissue.
Recommended to maintain daily health for
anyone exposed to COVID, vaccines, or shedding – and may help your
body repair itself and remain at optimal health.
Where to buy Spike Support Formula: Spike Support Formula is available on The Wellness
Company's website. Here is the link: Spike Support Formula (Long Haul Formula)
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
With only one of the biopharma industry’s top 20 revenue companies seeing a year-over-year decline in sales, 2024 was a remarkable year of revenue growth for the industry. Compare that to 2023, when eight of the top 20 drugmakers experienced revenue declines. Six of the top 20 drugmakers had double-digit increases in 2024, compared to just two in 2023. Five others saw a revenue bump of between 7% and 9%, compared to two reaching those figures in 2023. For the second year in a row, Eli Lilly (32%) and Novo Nordisk (26%) posted Big Pharma's largest year-over-year sales bumps, though their positions were flipped from 2023 when Novo (31%) topped Lilly (20%). Expect the same form in 2025 as Lilly—boosted by sales of its diabetes and obesity drugs Moujaro and Zepbound— projects its sales to fall between $58 billion and $61 billion. At the midpoint of the projection, it would be a 32% increase, matching the sales boom it saw last year. Meanwhile, Novo—which also has been powered by sale...
It's been several years since COVID-19 vaccines from Pfizer and Moderna jumped to the top of the pharma industry's sales charts, displacing longtime stalwarts with unprecedented sales. But, as 2023 featured major patent expirations, the rise of weight loss drugs and other new dynamics, the year’s ranking of the top 10 drugs by global sales featured its fair share of surprises. Merck’s oncology king Keytruda rose to the top last year, adding yet another feather in its cap. With more than 30 indications across various cancer types and stages, the PD-L1 inhibitor shows no signs of stopping. With $25 billion in global sales, the drug accounted for about 40% of Merck’s total revenue last year. Keytruda's sales are expected to reach $30 billion this year. Keytruda had previously fallen right behind AbbVie's Humira, which held the title of the world’s bestselling drug for nine years in a row until Pfizer and BioNTech’s Comirnaty knocked AbbVie’s Humira off its perch in 2021. N...
If you're looking for the best cryptocurrency exchanges in Malaysia in 2025, it's important to choose platforms that are secure and fully compliant with local regulations. In Malaysia, Digital Asset Exchanges (DAX) are regulated and licensed by the Securities Commission Malaysia (SC), which ensures they meet strict standards for investor protection and legal compliance. Luno, Binance, Sinegy, Tokenize Exchange, MX Global, Hata and Torum are popular choices. The best cryptocurrency exchanges work similarly to the best stock trading apps, offering competitive fees and resources on digital marketplaces like mobile or desktop. Crypto enthusiasts can easily buy, sell, and store popular digital currencies like Bitcoin or altcoins like Ethereum. Note that if you don't want to use your exchange's built-in wallet (if applicable), you'll need to set up an external crypto wallet, to store your assets securely. Here are details of cryptocurrency exchanges you can use to buy Bit...
Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boast shares within less than a percentage point of one another. And it won’t just be the heavy hitters clawing for a piece of the pie. That number is set to near...
Along with gold, silver is in high demand as precious metals are highly sought after as safe havens in uncertain economic environments, boosting prices and assets for top silver ETFs like the iShares Silver Trust (SLV). Investors use silver ETFs for various purposes. Other than its safe-haven benefits, some invest for speculative reasons, hoping to profit from potential increases in silver prices or as a hedge against geopolitical turmoil or currency devaluation. Keep reading to learn more about investing in silver and see a list of top ETFs investing in the precious metal. What Are Silver ETFs? Silver ETFs are exchange-traded funds that provide exposure to the price of silver, a precious metal. These ETFs are designed to track the performance of silver prices, making it easier for investors to gain exposure to the silver market without physically owning and storing the metal itself. Silver's unique combination of properties, including its electrical conductivity, thermal c...
In 2024, the pharmaceutical industry witnessed significant shifts in research and development (R&D) investments, with companies like Merck & Co. and AstraZeneca making notable strategic decisions that impacted their positions among top R&D spenders. The average cost for major pharmaceutical companies to develop a drug in 2024 rose to $2.23 billion, up from $2.12 billion the previous year. This increase reflects the growing complexity and expense associated with bringing new therapies to market. ( Fierce Biotech ) These developments illustrate the dynamic nature of R&D investments in the pharmaceutical sector, influenced by strategic partnerships, acquisitions, and the escalating costs of drug development. 1. Merck & Co. R&D SPENDING 2024: $17.9 billion Change from 2023: -41% Total 2024 revenue: $64.2 billion R&D budget as percentage of revenue: 28% Market capitalisation: 198.3 B USD (as of June 2025) Merck & Co.’s R&D spending plummeted from the d...
Incidents triggered by lithium-ion batteries are now, on average, a weekly occurrence on U.S. flights, according to the U.S. Federal Aviation Administration (FAA), with cabin crews expressing concern over the risk. This year, 69 lithium battery incidents involving smoke, fire, or extreme heat have occurred on U.S. flights as of Dec. 16, FAA data show. This equates to more than 1.3 incidents per week. Since 2015, the number of such events has increased by more than 330 percent. Between March 3, 2006, and Nov. 5, 2024, a total of 579 lithium battery incidents were recorded, with the majority of cases coming from passenger carriers. Battery packs and batteries accounted for the bulk of these incidents, with 229 events, followed by e-cigarettes/vape devices with 122, cell phones with 81, laptops with 70, and the rest involving other electronic and medical devices. On Nov. 5, a smoke detector alarm from the lavatory of a United Airlines flight coming from San Francisco went off. “Flight a...
On October 5, 2011, Steve Jobs died after a battle with a rare pancreatic cancer at age 56. But he may have lived longer if he sought proper medical care in time. When Apple co-founder Steve Jobs was first diagnosed with pancreatic cancer in 2003, his doctors advised him to seek surgery as soon as possible. Instead, he delayed the procedure for nine months and attempted to treat himself with alternative medicine. This fateful decision may have quickened Steve Jobs’ death — when he still could’ve been saved. Steve Jobs died from pancreatic cancer complications on October 5, 2011, just eight years after his initial diagnosis. He was only 56 years old when he died, but his cancer had taken such a toll on his body that he looked gaunt, frail, and much older than his actual age. It was a far cry from the robust, energetic man who had once pioneered the personal computer era. ...
Several banks in Malaysia offer business loans tailored for SMEs. Maybank and CIMB are popular choices, offering a variety of loan amounts and competitive interest rates. Other notable options include Public Bank and RHB, while SME Bank and MIDF also provide dedicated financing solutions for small and medium-sized enterprises. SME or also known as Small and Medium-sized Enterprises are businesses that maintain revenues, assets, or a number of employees below a certain threshold. These business entities are often regarded as the heartbeat of Malaysia’s emerging and developing economies. Apart from providing vast numbers of employment opportunities, SME businesses are generally entrepreneurial in nature, helping to shape innovation. Generally, there are two criteria to be met in order for your business to qualify as an SME -- your annual sales turnover and the number of full time employees in your company. This also implies differently for each economy sector: Manufacturing (S...
The correlation between the Nasdaq index and cryptocurrencies, particularly Bitcoin, has been a subject of interest and analysis, reflecting the increasing integration of digital assets into the broader financial ecosystem. Here's a detailed look at this relationship: Historical Context and Trends: Increasing Correlation : Over the past few years, there has been a noticeable trend towards a stronger correlation between Bitcoin and the Nasdaq Composite Index, especially with tech-heavy indices like the Nasdaq 100. As of early 2025, this correlation has been observed to be at a high level, with some periods showing a correlation coefficient above 0.9. This suggests that movements in Bitcoin prices often mirror those of the Nasdaq, particularly during bullish market phases for tech stocks. Institutional Influence : The growing involvement of institutional investors in cryptocurrencies has played a significant role in this correlation. Companies like Coinbase, which has a listing on Na...
Comments